Moving beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer

Urology

Volumn 89, Issue , 2016, Pages 10-11

  Chedgy, Edmund C P ^a   Black, Peter C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ATM PROTEIN; BRCA2 PROTEIN; DOCETAXEL; ENZALUTAMIDE; OLAPARIB; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANEMIA; CIRCULATING TUMOR CELL; DNA REPAIR; DRUG DOSE REDUCTION; DRUG EFFECT; FATIGUE; HUMAN; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; METASTATIC PROSTATE CANCER; MULTICENTER STUDY (TOPIC); NEXT GENERATION SEQUENCING; NOTE; OVERALL SURVIVAL; PATIENT HISTORY OF THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TREATMENT DURATION; TREATMENT RESPONSE; PROSTATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; DNA REPAIR; ENZYME INHIBITORS; HUMANS; MALE; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROSTATIC NEOPLASMS;

EID: 84961199136     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2015.12.002     Document Type: Letter

References (8)

1. E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
2. A.M. Oza, D. Cibula, A.O. Benzaquen, and et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial Lancet Oncol 16 2015 87 97
3. G. Attard, C. Parker, R.A. Eeles, and et al. Prostate cancer Lancet 2015 10.1016/S0140-6736(14)61947-4
4. B. Kaufman, R. Shapira-Frommer, R.K. Schmutzler, and et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation J Clin Oncol 33 2015 244 250
5. K. Fizazi, H.I. Scher, A. Molina, and et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
6. H.I. Scher, K. Fizazi, F. Saad, and et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
7. A.A. Azad, S.V. Volik, A.W. Wyatt, and et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer Clin Cancer Res 21 2015 2315 2324
8. A. Romanel, D.G. Tandefelt, V. Conteduca, and et al. Plasma AR and abiraterone-resistant prostate cancer Sci Transl Med 7 2015 312re310